Delcath announces inducement grants under nasdaq listing rule 5635(c)(4)

Queensbury, n.y.--(business wire)--delcath systems, inc. (nasdaq: dcth) (the “company” or “delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the company granted three equity awards, previously approved by the company's compensation committee, as a material inducement to the employment of three individuals whose employment commenced in august 2024. the grants totaled the right to purchase an aggregate of 46,000 s.
NDAQ Ratings Summary
NDAQ Quant Ranking